Business Context and Reporting Period
This Form 8-K Current Report was filed by Flex Pharma, Inc. on May 9, 2016. The filing discloses the entry into a material definitive agreement and changes in executive management responsibilities in anticipation of the launch of a consumer product designed to prevent and treat exercise-associated muscle cramps.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on contractual agreements and personnel changes rather than financial performance data.
Material Changes and Agreements
Supply Agreement with Trilogy Essential Ingredients Inc.
- Parties: Flex Innovation Group LLC (a wholly owned subsidiary of Flex Pharma) and Trilogy Essential Ingredients Inc.
- Scope: Trilogy agreed to manufacture and supply specific ingredients for the Company's consumer product.
- Exclusivity: Trilogy is designated as the sole U.S. provider of these ingredients for a two-year period.
- Pricing: Based on a per-pound price, subject to adjustments defined in the agreement.
- Term: Initial term of two years with automatic one-year renewals unless terminated by written notice.
- Termination: Either party may terminate for material breach; Flex Innovation may terminate at any time with written notice.
- Confidentiality: The full agreement will be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2016, with portions subject to confidential treatment.
Executive Management Changes
- Katharine Lindemann (COO): Assumed responsibility for managing the operations of the Company's consumer group.
- Marina Hahn (President, Consumer): Will continue in her role, providing strategic and marketing guidance.
- Compensation Amendment: An amendment to Ms. Hahn's offer letter was executed on May 9, 2016. It accelerates a portion of her previously granted stock options if she is terminated without Cause prior to December 31, 2016.
Guidance, Outlook, and Risks
The Company is preparing for the launch of its consumer product targeting exercise-associated muscle cramps. The filing does not contain specific financial guidance or quantitative risk factors. The primary operational risk noted is the reliance on Trilogy as the sole U.S. supplier for key ingredients, though the agreement includes termination rights and last time buy provisions.
Investor Verification Checklist
- Verify the specific pricing terms and adjustment mechanisms in the Supply Agreement with Trilogy once filed in the Form 10-Q.
- Confirm the timeline for the consumer product launch and initial sales projections.
- Review the full text of the amendment to Marina Hahn's offer letter (Exhibit 10.1) to understand the specific vesting acceleration triggers.
- Monitor future filings for any material breaches or terminations of the exclusive supply agreement.